Related references
Note: Only part of the references are listed.Targeting Chemokine-Glycosaminoglycan Interactions to Inhibit Inflammation
Helena Crijns et al.
FRONTIERS IN IMMUNOLOGY (2020)
Exhausted CD8+ T cells exhibit low and strongly inhibited TCR signaling during chronic LCMV infection
Ioana Sandu et al.
NATURE COMMUNICATIONS (2020)
The healthy exocrine pancreas contains preproinsulin-specific CD8 T cells that attack islets in type 1 diabetes
Christine Bender et al.
SCIENCE ADVANCES (2020)
Re-defining T-Cell Exhaustion: Subset, Function, and Regulation
Se Jin Im et al.
IMMUNE NETWORK (2020)
Unique Inflammatory Changes in Exocrine and Endocrine Pancreas in Enterovirus-Induced Fulminant Type 1 Diabetes
Mikako Takita et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Immune cell trafficking to the islets during type 1 diabetes
A. M. Sandor et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2019)
L-selectin: A Major Regulator of Leukocyte Adhesion, Migration and Signaling
Aleksander Ivetic et al.
FRONTIERS IN IMMUNOLOGY (2019)
Chemokines in rheumatic diseases: pathogenic role and therapeutic implications
Yoshishige Miyabe et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
The Many Roles of Cell Adhesion Molecules in Hepatic Fibrosis
Edith Hintermann et al.
CELLS (2019)
Pathogen infection and autoimmune disease
U. Christen
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2019)
Enterovirus infection and type 1 diabetes: unraveling the crime scene
T. Rodriguez-Calvo
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2019)
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7years from diagnosis
Ana Luisa Perdigoto et al.
DIABETOLOGIA (2019)
Modulation of the diet and gastrointestinal microbiota normalizes systemic inflammation and beta-cell chemokine expression associated with autoimmune diabetes susceptibility
Angela M. Henschel et al.
PLOS ONE (2018)
Comparison of Acute Gene Expression Profiles of Islet Cells Obtained via Laser Capture Microdissection between Alloxan- and Streptozotocin-treated Rats
Yuki Kato et al.
TOXICOLOGIC PATHOLOGY (2018)
Suppression of diabetes by accumulation of non-islet-specific CD8(+) effector T cells in pancreatic islets
Gustaf Christoffersson et al.
SCIENCE IMMUNOLOGY (2018)
Characterization of resident lymphocytes in human pancreatic islets
M. Radenkovic et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
Islet-Expressed CXCL10 Promotes Autoimmune Destruction of Islet Isografts in Mice With Type 1 Diabetes
Christine Bender et al.
DIABETES (2017)
Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES
Pauline Bonvin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Progression of type 1 diabetes from the prediabetic stage is controlled by interferon-α signaling
Brett S. Marro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Comparative quantitative proteomic analysis of disease stratified laser captured microdissected human islets identifies proteins and pathways potentially related to type 1 diabetes
Julius O. Nyalwidhe et al.
PLOS ONE (2017)
Pancreatic β-Cell-Derived IP-10/CXCL10 Isletokine Mediates Early Loss of Graft Function in Islet Cell Transplantation
Gumpei Yoshimatsu et al.
DIABETES (2017)
Recovery of high-quality RNA from laser capture microdissected human and rodent pancreas
Alexandra E. Butler et al.
JOURNAL OF HISTOTECHNOLOGY (2016)
Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes
S. Alice Long et al.
SCIENCE IMMUNOLOGY (2016)
Anti-CD3/Anti-CXCL10 Antibody Combination Therapy Induces a Persistent Remission of Type 1 Diabetes in Two Mouse Models
Stanley Lasch et al.
DIABETES (2015)
Chemokine receptors as therapeutic targets: Why aren't there more drugs?
Roberto Solari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Maraviroc: a review of its use in HIV infection and beyond
Shawna M. Woollard et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Detection of a Low-Grade Enteroviral Infection in the Islets of Langerhans of Living Patients Newly Diagnosed With Type 1 Diabetes
Lars Krogvold et al.
DIABETES (2015)
Gene expression analysis of human islets in a subject at onset of type 1 diabetes
Johan Hopfgarten et al.
ACTA DIABETOLOGICA (2014)
Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity
Jason W. Griffith et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes
Ronnie Aronson et al.
DIABETES CARE (2014)
Anti-TCR therapy combined with fingolimod for reversal of diabetic hyperglycemia by β cell regeneration in the LEW.1AR1-iddm rat model of type 1 diabetes
Anne Joerns et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
Antibody-Validated Proteins in Inflamed Islets of Fulminant Type 1 Diabetes Profiled by Laser-Capture Microdissection Followed by Mass Spectrometry
Yoriko Nishida et al.
PLOS ONE (2014)
Insulitis in human type 1 diabetes: a comparison between patients and animal models
Peter In't Veld
SEMINARS IN IMMUNOPATHOLOGY (2014)
Anti-CD3 clinical trials in type 1 diabetes mellitus
Anastasia G. Daifotis et al.
CLINICAL IMMUNOLOGY (2013)
The Peri-islet Basement Membrane, a Barrier to Infiltrating Leukocytes in Type 1 Diabetes in Mouse and Human
Eva Korpos et al.
DIABETES (2013)
Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes
Changyun Hu et al.
DIABETES (2013)
Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders
Kevan C. Herold et al.
DIABETES (2013)
Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes
William Hagopian et al.
DIABETES (2013)
Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis
Janine Ehser et al.
JOURNAL OF AUTOIMMUNITY (2013)
Defining the Transcriptional and Cellular Landscape of Type 1 Diabetes in the NOD Mouse
Javier A. Carrero et al.
PLOS ONE (2013)
Therapeutic Use of a Selective S1P1 Receptor Modulator Ponesimod in Autoimmune Diabetes
Sylvaine You et al.
PLOS ONE (2013)
Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients
M. Andrade Lima Gabbay et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2012)
Expression and Regulation of Chemoldnes in Murine and Human Type 1 Diabetes
Suparna A. Sarkar et al.
DIABETES (2012)
Low doses of anti-CD3, ciclosporin A and the vitamin D analogue, TX527, synergise to delay recurrence of autoimmune diabetes in an islet-transplanted NOD mouse model of diabetes
F. Baeke et al.
DIABETOLOGIA (2012)
Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice
Tatiana Takiishi et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients
Ken T. Coppieters et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Analysis of Beta-Cell Gene Expression Reveals Inflammatory Signaling and Evidence of Dedifferentiation following Human Islet Isolation and Culture
Sarita Negi et al.
PLOS ONE (2012)
Targeting chemokine receptors in chronic inflammatory diseases: An extensive review
Pim J. Koelink et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Do viral infections protect from or enhance type 1 diabetes and how can we tell the difference?
Urs Christen et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2011)
Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial
Nicole Sherry et al.
LANCET (2011)
Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies
Wing-Chi G. Yeung et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Islet inflammation and CXCL10 in recent-onset type 1 diabetes
B. O. Roep et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass
B. Keymeulen et al.
DIABETOLOGIA (2010)
Expression of chemokines, CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islets of patients with recent-onset autoimmune type 1 diabetes
Sae Uno et al.
ENDOCRINE JOURNAL (2010)
Viral triggers for autoimmunity: Is the 'glass of molecular mimicry' half full or half empty?
Urs Christen et al.
JOURNAL OF AUTOIMMUNITY (2010)
Enterovirus Infection, CXC Chemokine Ligand 10 (CXCL10), and CXCR3 Circuit A Mechanism of Accelerated β-Cell Failure in Fulminant Type 1 Diabetes
Shoichiro Tanaka et al.
DIABETES (2009)
Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study
A. Antonelli et al.
DIABETIC MEDICINE (2008)
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection
Martin Holdener et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Moving targets: cell migration inhibitors as new anti-inflammatory therapies
Charles R. Mackay
NATURE IMMUNOLOGY (2008)
CD3-specific antibodies: a portal to the treatment of autoimmunity
Lucienne Chatenoud et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs
D Bresson et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Altered chemokine levels in individuals at risk of Type 1 diabetes mellitus
P Hanifi-Moghaddam et al.
DIABETIC MEDICINE (2006)
Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development
A Rhode et al.
JOURNAL OF IMMUNOLOGY (2005)
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
B Keymeulen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A viral epitope that mimics a self antigen can accelerate but nit initiate autoimmune diabetes
U Christen et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Among CXCR3 chemokines, IFN-γ-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-γ (CXCL9) imprints a pattern for the subsequent development of autoimmune disease
U Christen et al.
JOURNAL OF IMMUNOLOGY (2003)
to:: !Nicoletti F, !Conget L, !DiMauro M et al. (2002) -: Serum concentrations of the interferon-α-inducible chemokine IP-10/CXCL10 are augmented in both newly-diagnosed Type 1 diabetes mellitus patients and subjects at risk of developing the disease.
M Rotondi et al.
DIABETOLOGIA (2003)
IL-1β and IFN-γ induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice
AK Cardozo et al.
DIABETOLOGIA (2003)
Autoimmune islet destruction in spontaneous type 1 diabetes is not β-cell exclusive
S Winer et al.
NATURE MEDICINE (2003)
Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease
F Nicoletti et al.
DIABETOLOGIA (2002)
Elevated serum IP-10 levels observed in type 1 diabetes
A Shimada et al.
DIABETES CARE (2001)
IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection
IA Khan et al.
IMMUNITY (2000)
Share Paper
